- InnoCare Pharma, listed in Hong Kong and Shanghai, said on 24 September 2026 that it has signed a strategic research collaboration and licence agreement with Eli Lilly. InnoCare will use its discovery platform to find and advance compounds against up to 5 targets. Neither the targets nor the therapeutic areas were disclosed.
- InnoCare is eligible for up to $100m in upfront and near-term payments, up to about $3.25bn in development and commercial milestones, and single-digit tiered royalties on net sales. The release adds a cautionary note that the payments are subject to conditions and that the final amount remains uncertain.
- InnoCare is a commercial-stage company focused on cancer and autoimmune disease, with 3 approved drugs (orelabrutinib, tafasitamab and zurletrectinib) and more than 10 candidates in clinical development. It reported first-half 2026 revenue growth of 55.5% and a profit of RMB239.7m, turning around from a loss a year earlier.
- Chairwoman and chief executive Jasmine Cui said the company is dedicated to expanding its partnerships. Earlier this month InnoCare cleared a clinical trial in China for ICP-B381, a bispecific antibody-drug conjugate against PSMA and STEAP1 and its third ADC to reach the clinic.
Deal read
This is the most transparent discovery deal of the past eight days, and it still blends the one number that matters.
- The near-term money is about 3% of the maximum. Upfront and near-term payments are combined at $100m, against a total of about $3.35bn. Spread across five targets, that is roughly $20m each in near-term money against up to $650m each in milestones, and even the $100m is not all paid at signing.
- It still sets this week’s disclosure bar. Orbis with Novo Nordisk, BoomRay with Novartis and Envisagenics with Boehringer Ingelheim all folded their upfronts into a headline total, and Henlius disclosed no amounts at all. InnoCare at least separates a near-term tranche, and its own release warns that the final payment is uncertain.
- The seller does not need the cash. InnoCare is profitable, with three approved drugs, and is renting out discovery capacity while keeping its clinical pipeline. That contrasts with Envisagenics, which is using partner money to fund its lead programme. It is also the second China-to-big-pharma licence in eight days, after BoomRay with Novartis.